ASCO Guideline Update: Systemic therapy for advanced human epidermal growth factor receptor 2–positive breast cancer.
1 Jun, 2022 | 11:38h | UTC
Commentary on Twitter
Out on JCO the latest @ASCO Guidelines Update on the treatment of HER2-positive ABC. Key points: standard first line remains THP, new second line is T-DXd, no standard after progression to T-DXd, a setting for which we urgently need data.https://t.co/2mMxBLACmf pic.twitter.com/2sXpzqz4ym
— Paolo Tarantino (@PTarantinoMD) June 1, 2022